Creative Medical Technology Holdings, Inc. Share Price & Technical Analysis
CELZ · $2.39 (+3.02%)
Healthcare / Biotechnology
$2.39
+3.02%
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
4% return in May, -4% avg return in past 3 year May month.
21% return in 2026, 13% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | -10% | 17% | 10% | 4% | – | – | – | – | – | – | – | 21% |
| 25 | 35% | 61% | -58% | 0% | 5% | 23% | 8% | 14% | 6% | -3% | -13% | -26% | 52% |
| 24 | -11% | 0% | 24% | -15% | -7% | -12% | -3% | 6% | -11% | 37% | -34% | -15% | -41% |
| 23 | 39% | 2% | -12% | 33% | -10% | -23% | 17% | -16% | 7% | -10% | 0% | 2% | 28% |
| 22 | -37% | -12% | 122% | -48% | -52% | -26% | -3% | -7% | -35% | -4% | -7% | -5% | -114% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Emerging · Strong
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$8.26M
P/E ratio
—
52W high
$6.25
52W low
$1.50
Volume
47,690
Beta
1.85
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Creative Medical Technology Holdings, Inc. share price today?
- Creative Medical Technology Holdings, Inc. (CELZ) last traded around $2.39 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CELZ have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CELZ. Download the app for real-time alerts.
- How can I analyze Creative Medical Technology Holdings, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.